Last updated: 2026-10-08 11:50:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
CDT Equity Inc. (CDT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0,83, with a market capitalization of $716,85K and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,80 to $37 490,00. This page covers its latest market performance, valuation, price trends and company information.
$716,85K | |
$0,83 | |
$1 680 000 000,00 | |
$0,80 | |
$0,84 | |
26,83K | |
187,52K | |
-- | |
$37 490,00 | |
$0,80 | |
-- | |
-- |
CDT Equity Inc. (CDT) is trading at $0,83 in pre-market trading as of 2026-10-08 11:43:00, down 0,48% ($0,00) from the previous close of $0,84
Pre-market trading shows how investors are pricing CDT before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, CDT Equity Inc. (CDT) moved from $1,45 to $0,83, representing a decline of 42,62% ($0,62).
The stock traded between $0,80 and $1,88 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 570,16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,0%
CDT is currently trading at $0,83, placing it 0,0% of the way from its 52-week low of $0,80 to its 52-week high of $37 490,00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CDT Equity Inc. (CDT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.